- Policy
- The MFDS supports ₩25.6 billion for COVID-19
- by Lee, Tak-Sun Sep 4, 2020 06:53am
- The MFDS has established a budget of &8361;25.6 billion next year to support the commercialization of COVID-19 vaccines and K-quarantine products. The MFDS announced on the 2nd that the government budget for 2021 has increased by &8361;45.2 billion (8.1%) from &8361;559.2 billion this year to a total of &8361;604.4 billion. The budget
- Company
- Celebrex barrier still too high for NSAID Acelex
- by Nho, Byung Chul Sep 4, 2020 06:52am
- The 22nd Korean-made novel drug (Bio-venture No. 1) and a nonsteroidal anti-inflammatory drug (NSAID) for arthritis Acelex (polmacoxib) seems to be stuck in a box pattern, struggling to narrow the sales gap with its biggest competitor Celebrex (celecoxib). IQVIA data found Acelex has generated 598 million won, 4.01 billion won, 4.78 bill
- Opinion
- [Reporter’s View] A salesperson who lost a place to go
- by Kim, Jin-Gu Sep 4, 2020 06:52am
- "I went to work today, but I was just sitting in the car. I couldn't do anything other than that." Mr. A, who works as a salesperson for a pharmaceutical company in the metropolitan area, complained with frustration. He sat in the car for lunch with kimbap today. He couldn't even go to a cafe. He opened his laptop from the driver's seat, d
- Company
- Galderma Korea appoints Younhee Kim as the new CEO
- by Eo, Yun-Ho Sep 3, 2020 12:55pm
- Galderma Korea has appointed Younhee Kim, former general manager of the Medical Solution Division, as the new CEO. According to related industries, CEO Kim started official business as the official president on the October 1st. Rene Wipperich, former CEO of Galderma's Korean subsidiary for two years from September 2018, has been confirmed
- Policy
- DREC and Cancer Committee to convene more on-paper meetings
- by Lee, Hye-Kyung Sep 3, 2020 06:29am
- The South Korean government is to alleviate on-paper deliberations related regulation for the first threshold of pharmaceutical reimbursement listing&8212;the Drug Reimbursement Evaluation Committee (DREC) and Cancer Deliberation Committee. The Health Insurance Review and Assessment Service (HIRA) preannounced partially revised manageri
- Policy
- Celltrion's COVID-19 antibody treatment phase I completed
- by Lee, Tak-Sun Sep 3, 2020 06:27am
- The MFDS announced on the 1st that the COVID-19 antibody treatment drug Celltrion is developing has completed phase I clinical administration and is currently under review of phase II/III trial plans. The MFDS announced the progress of the COVID-19 treatment and vaccine clinical trials in the explanatory data. Celltrion's new drug (CT-P59)
- Policy
- IND for AK-216 (Vildagliptin) by Alvogen Korea was approved
- by Lee, Tak-Sun Sep 3, 2020 06:27am
- Alvogen Korea is launching a phase III clinical trial of Vildagliptin, a diabetes treatment of DPP-4 inhibition. It is entering phase III in 9 months after approval of clinical trial I in November of last year. However, the effectiveness with Metformin, not monotherapy, are verified. While generics for Galvus are aiming for an early release
- Policy
- 2021 MOHW budget KRW 90.15 tln--KRW 131 bln on COVID-19
- by Kim, Jung-Ju Sep 3, 2020 06:27am
- South Korea’s Ministry of Health and Welfare (MOHW) has finalized next year’s budget plan with 90 trillion won. The state funding for National Health Insurance (NHI) has been raised to 9.5 trillion won. 131.4 billion won was allocated on providing support on R&D seeking COVID-19 treatment and vaccine. Moreover, the state-led new drug R&D p
- Company
- Sales of immunotherapy for Cancer are ↑18 times in 4 years
- by An, Kyung-Jin Sep 2, 2020 06:19am
- Immunotherapy for Cancer is expanding rapidly in the domestic pharmaceutical market. The domestic immune checkpoint inhibitor market started with Yervoy (Ipilimumab), Keytruda (Pembrolizumab), and Opdivo (Nivolumab), and generics such as Tecentriq (Atezolizumab) and Imfinzi (Durvalumab) were added one after another, sales increased by 18 t
- Company
- AZ Korea Director Chon as a new Country President Indonesia
- by Eo, Yun-Ho Sep 2, 2020 06:18am
- Chon Sewhan, a director at AstraZeneca Korea, has been promoted as a Country President at PT. AstraZeneca Indonesia The industry sources reported the current Cardiovascular, Renal and Metabolic Diseases (CVRM) Business Unit Director, Chon Sewhan, has been appointed as a Country President Indonesia as of Sept. 1. Started off his career
